Nouscom AG
Developing next generation immunotherapies to beat cancer
Our strategy stems from recent therapeutic achievements in the fields of checkpoint inhibitors, therapeutic antibodies, cancer vaccines and oncolytic viruses. We plan to develop a series of new, potent immunotherapeutics capable of selectively killing tumor cells. Our immunotherapeutics embody the best features of oncolytic viruses and therapeutic antibodies, and include viral vectored genetic vaccines based on patient- and tumor-specific antigens.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
13.10.2025
Clinical milestones bring startups closer to launching new therapies (startupticker.ch)
09.05.2025
Milestones achievements for life sciences startups (startupticker.ch)
08.04.2025
Key advancements in the biotech and medtech landscape (startupticker.ch)
11.12.2024
New leaders with a fresh perspective for several startups (startupticker.ch)
25.11.2024
POWHER Awards für drei Unternehmerinnen (startupticker.ch)
No milestones
No Jobs
No videos and documents
No Awards
Nouscom AG
Developing next generation immunotherapies to beat cancer
Website:
www.nouscom.com
Headquarter:
Basel
Foundation Date:
January 2015
Technology:
- Biotech
Sectors:
- Cancer